‘Keep away from the doctor’: a visit to an influencer’s wellness event, where the advice could kill - The Guardian

In 2026, anybody can cultivate a massive social media following doing anything their heart desires — and that's not necessarily a good thing. For a case in point, look no further than a recent Reel from holistic health influencer Matt Roeske. First spotted by the publication Reality Check, the clip features Roeske promoting radioactive water as a long-forgotten panacea, supposedly shut down by the "Rothschild medical system. "In his video, Roeske appears holding a "Revigator," an irradiated ceramic jug from the 1920s sold as a pseudoscientific miracle cure-all. In addition to carnotite — a bright-yellow rock known for its high uranium content — the Revigator contains a slew of chemicals like arsenic, lead, and vanadium, which is all stuff you shouldn't even shower with, let alone mix in your drinking water. "You see all that beautiful water in there? " Roeske asks while tilting the cistern toward the camera. "Perfectly harmless, you've just been lied to," he says before taking a huge mouthful of the stuff. "And it's delicious. And I've been drinking it for 250 days now.

Patients receiving oral anticoagulation (OAC) for atrial fibrillation frequently have concomitant coronary artery disease (CAD), raising questions about the duration of additional antiplatelet therapy. Triple antithrombotic therapy combines OAC with aspirin and a P2Y₁₂ inhibitor, usually clopidogrel, whereas dual antithrombotic therapy combines OAC with a single antiplatelet agent. Early aspirin withdrawal from triple therapy and subsequent withdrawal of the remaining antiplatelet are separate decisions requiring assessment of the coronary timeline and current treatment indications. This narrative editorial examines randomized evidence and proposes a structured medication review framework. The evidence generally supports OAC monotherapy in appropriately selected patients with stable CAD, with reduced bleeding and favourable net clinical outcomes compared with combined treatment. However, aspirin-specific findings require distinction from comparisons involving clopidogrel or mixed antiplatelet regimens. Overall trial results do not establish identical benefits or harms across patients with previous myocardial infarction, multivessel disease, or complex coronary intervention. Differe

News • Trial investigates combined benefits A new clinical trial will investigate whether a simple blood test could help detect breast cancer as early as Stage I

A next-generation total-body PET/CT scanner can produce diagnostic-quality images in as little as 1 minute of scanning, according to research presented today at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM'26). Even its fastest images were rated more highly on average than those from a standard PET/CT scanner. PET/CT is widely used to diagnose, stage and monitor cancer. Conventional PET/CT scanners have a short axial field of view, meaning they image the body section by section, typically requiring five to six 'bed positions' to cover the body from head to thigh. Long-axial field-of-view (LA-FOV) systems capture a much larger part of the body at once and detect more of the signal emitted by the radiotracer, raising the possibility of much shorter scans without sacrificing image quality.

MALABO, Equatorial Guinea (AP) — With its torrential rains, tropical forests and omnipresent humidity, Equatorial Guinea provides the perfect conditions for mosquitoes to breed. For centuries, mosquito-borne diseases, in particular malaria, have dictated the fate of residents of this central African nation, impacting how they lived, worked and died. But Bioko island, off mainland Equatorial Guinea, has managed to sharply reduce malaria infections and deaths. Bioko, roughly half the size of Rhode Island, has used familiar tools: indoor spraying, mosquito nets and keeping control of the larvae population. Its success, however, has depended on something less easily replicated: two decades of painstaking data collection, sustained funding and workers going door to door to win residents' trust. Now the tiny, oil-rich country wants to bring that approach to its mainland and eliminate malaria altogether. But the expansion of Bioko's strategy presents formidable challenges, from porous international borders to the sheer scale of the territory.

A hospital that has implanted tiny pacemakers for 10 years has been recognised as a "centre of excellence". Northampton General Hospital said the honour, bestowed by the manufacturer, was for the way "it has pioneered" the fitting of the leadless pacemaker and for training other teams around the UK. The device is 93% smaller than traditional pacemakers, weighs about two grams and can be inserted in about 20 minutes. It is so small that it cannot be felt under the surface of the skin, the trust explained. The device, made by global US healthcare company Medtronic, has been used in Northampton since 2016 and in 2024 it became the first hospital trust in the UK to use the latest form. The trust has fitted it in about 300 patients so far. Staff Northampton General Hospital were treated with a cake to mark the achievement [NGH]Dr David Sharman, a consultant cardiologist who implanted the hospital's first device, said his team had been training specialist nurses, cardiac physiologists and radiographers from across England. "This kind of pacemaker is the future for pacemakers," he said. Do you have a story suggestion for Northamptonshire? Contact us below.